A comprehensive study based on large-sample multi-omics integration and machine learning to decode mitochondria-associated genes: from digestive tract tumours to gastric cancer
New insights are provided into the differential expression and pathogenesis of LACTB2 in digestive tract tumours, particularly its prognostic and diagnostic value in GC.
Abstract
Background Mitochondria-related genes play a crucial role in driving tumour cell progression, but little is known about their molecular mechanisms and biological pathways. This study conducted a comprehensive analysis of the mitochondrial key gene LACTB2 in digestive tract tumours and explored a novel early blood-based diagnostic model for gastric cancer (GC). Methods This study analyzed LACTB2 expression, biological pathways, and immune regulation in a large cohort of 10,581 samples. IHC staining was performed using 236 internal GC samples. Multi-omics data were integrated for comprehensive analysis of LACTB2 in GC. A combination of extensive clinical samples and multiple machine learning models enabled the construction of prognostic and blood-based diagnostic models (n = 14,219). Results LACTB2 overexpression is associated with clinical metastasis and the activation of pro-cancer pathways, and LACTB2 may mediate immune suppression and immune evasion through various methods. There is a significant transcriptional regulatory network upstream of LACTB2. LACTB2 overexpression may drive malignant transformation of GC epithelial cells through pro-cancer metabolic signalling networks, and the related mechanisms were spatially validated. Dysregulated expression of LACTB2 can affect the prognosis of GC patients, and Afatinib and Ulixertinib may play a significant role in targeting LACTB2 in the treatment of GC patients. An excellent early blood diagnostic model for GC was constructed based on the upstream miRNA of LACTB2. Conclusion Our study provides new insights into the differential expression and pathogenesis of LACTB2 in digestive tract tumours, particularly its prognostic and diagnostic value in GC.
This study delineates the molecular heterogeneity associated with lactylation-related gene expression in ccRCC and presents a validated prognostic model that identifies CDT1 as a novel oncogene and potential biomarker, providing insights into metabolic–epigenetic crosstalk and a foundation for future therapeutic develo...
Yue Zhang, Hang Zhou, Bihui Zhang et al.· Frontiers in Endocrinology· 0 citations
A comprehensive single-cell atlas of the BrM TME is unveiled and a robust 12-gene BrM-informed prognostic signature for LUAD is established, validated across multiple LUAD survival cohorts.
Jing-Xiang Pang, Wentian Wu, Peiwen Zhu et al.· Cancer Cell International· 0 citations
Heterogeneity in cancer‐associated fibroblast (CAF) infiltration within the tumor microenvironment is closely associated with gastric cancer progression and immune evasion; however, precise CAF‐related diagnostic markers and actionable therapeutic targets remain scarce.
Si-Hui Hou, Meng-Zhu Sang, Yan Wang et al.· Journal of Gastroenterology...· 0 citations
The MDrisk signature derived from mitochondrial energy metabolism and drug resistance may be useful for distinguishing prognosis, immune contexture, and computationally inferred drug susceptibility in LUAD.
Chengyang Wu, Rui Jiao, Han Yan et al.· Frontiers in Medicine· 0 citations
This study systematically characterizes acetylation-related genes in GBC, develops a high-accuracy diagnostic model, and provides preliminary insights into potential links between epigenetic regulation and the immune microenvironment.
At single-cell resolution, ZBTB21 emerges as a metabolic regulator that strengthens serine biosynthesis and redox homeostasis and provides mechanistic insights and potential strategies for metabolic-targeted therapies in CRC.
Yimei Jiang, Hai-Yan Huang, Haoran Feng et al.· Cancer Immunology and Immuno...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.